Zealand's interim report for the first half of 2016

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Zealand's interim report for the first half of 2016 (unaudited)

GLOSTRUP, Denmark, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Company announcement - No. 33 / 2016

Zealand's interim report for the first half of 2016 (unaudited)               

- Financial results as expected and in July, the first Zealand invented product was approved in the U.S.

  • Revenue of DKK 14.7 million / €2.0 million
  • Net loss of DKK 175.7 million / €23.6 million
  • Cash position of DKK 423.2 million / €56.9 million as of end June 2016  
  • iGlarLixi received a positive 12-2 vote by an FDA Advisory Committee recommending its approval to treat type 2 diabetes  
  • Agreement with Beta Bionics on clinical development of dasiglucagon [1] (ZP4207) for use in a dual-hormone artificial pancreas system

Events after the reporting period:

  • Lixisenatide approved by the FDA as Adlyxin TM to treat type 2 diabetes
  • Positive Phase II results with single-dose dasiglucagon (ZP4207) support its potential as a ready-to-use rescue pen to treat severe hypoglycemia
  • FDA extended the review time of iGlarLixi by three months. Regulatory decision expected end November 2016

Copenhagen, 25 August 2016 - Zealand Pharma A/S ("Zealand") (CVR no. 20 04 50 78) today reported financial results for the half-year period 1 January - 30 June 2016. Results were as expected and the financial guidance for 2016 remains unchanged.

Britt Meelby Jensen, President and CEO of Zealand , commented on the report: "This has been an exciting period for Zealand. We report financial results as expected, we confirm our full-year guidance, and we have had important advancements in our product portfolio. Lixisenatide, with the U.S. brand name Adlyxin TM , received FDA approval to treat adults with type 2 diabetes. Despite the recently announced three months' extension to the FDA review time for iGlarLixi, I expect 2016 to become the most successful year for Zealand, with an anticipated approval of this product in the U.S. as well. I am pleased with the continuously strong momentum in the development of our own product candidates. We have had positive Phase II results with our single-dose dasiglucagon, or ZP4207, for acute, severe hypoglycemia and we are in preparations to start the next clinical trial of multiple-dose dasiglucagon in a dual-hormone artificial pancreas system. Finally, our Phase II trial with glepaglutide [2] , or ZP1848, for short bowel syndrome is progressing well."

Financial highlights for H1 2016

  • Revenue of DKK 14.7million / €2.0 million (H1 2015: DKK 13.3 million / €1.8 million).
  • Net operating expenses of DKK 165.4 million / €22.2 million (H1 2015: DKK 125.9 million / €16.9 million).
  • Net loss of DKK 175.7 million / €23.6 million (H1 2015: DKK 131.8 million / €17.7 million).
  • The cash position amounted to DKK 423.2 million / €56.8 million at 30 June 2016 (30 June 2015: DKK 468.6 million / €62.8 million).

Restatements In connection with the preparation of the interim report for the first half of 2016, Zealand reviewed its accounting policy related to functional currency, income tax benefit and its royalty bond, along with reviewing a number of other items including the presentation of certain items within the statement of financial position. This review led to a number of restatements impacting the prior period income statements, statements of comprehensive loss, statement of cash flow, statement of financial position and statement of changes in equity.

The restatements have had a total impact on net loss and total comprehensive loss for the three and six months ended 30 June 2015 of respectively DKK -1.7 million and DKK 0.8 million. The restatements have had no impact on net loss or total comprehensive loss for the year ended 31 December 2015.

The nature and impact of the restatements are described in further details in Note 1 of the condensed consolidated interim financial statements.

Portfolio of out-licensed products - First product approved in the U.S.

Adlyxin TM /Lyxumia ® (lixisenatide) for type 2 diabetes (license collaboration with Sanofi)

  • Royalty revenue to Zealand on Sanofi's sales of Lyxumia ® amounted to DKK 13.1 million / € 1.7 million in H1 2016, a decrease of 3% compared to the same period of 2015. Sanofi reported flat sales of Lyxumia ® for the period measured at constant exchange rates. Lyxumia ® is approved in more than 60 countries and has been launched by Sanofi in 42 of these. The biggest markets for Lyxumia ® are the UK, Spain, Italy and Japan. Additional launches are planned for 2016-2018.
  • Late July, lixisenatide was approved by the U.S. FDA under the brand name Adlyxin TM for the treatment of adults with type 2 diabetes. This triggered a $5 million milestone payment from Sanofi.  

iGlarLixi (fixed-ratio combination of lixisenatide and Lantus ® ) for type 2 diabetes (license collaboration with Sanofi)

  • On 19 August 2016, the U.S. FDA decided to extend the regulatory review time for Sanofi's New Drug Application (NDA) for iGlarLixi by three months. The decision followed the submission by Sanofi of additional information, requested by the FDA, on the pen device for delivery of iGlarLixi as part of the NDA. A U.S. regulatory decision on iGlarLixi is now expected before the end of November 2016.
  • In May 2016, the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA recommended, by a vote of 12 to 2, the approval of the NDA for iGlarLixi.
  • iGlarLixi is also undergoing review by the European Medicines Agency (EMA) with a regulatory decision for Europe expected in Q1 2017.

Elsiglutide (GLP-2 analog) for chemotherapy-induced diarrhea (license collaboration with Helsinn)                                                                                                                                                          

  • In May 2016, a Phase IIb trial of elsiglutide for the treatment of chemotherapy induced diarrhea failed to meet its primary endpoint.
  • Helsinn is evaluating the full Phase II data set as well as results from a large, observational study of chemotherapy-induced diarrhea in consideration of next possible steps in the development of elsiglutide. A decision is expected later in H2 2016.

Boehringer Ingelheim license agreements - Novel treatments for diabetes and obesity

  • Zealand has two therapeutic peptide projects under license collaborations with Boehringer Ingelheim. One covers glucagon/GLP-1 dual agonists for the treatment of diabetes and/or obesity, and the other covers novel compounds against an undisclosed biological target for the treatment of obesity and/or diabetes.
  • Under both collaborations a lead candidate is being progressed towards start of clinical Phase I development in 2017.

Progress in the pipeline of proprietary drug candidates

Glepaglutide [3] (ZP1848, long-acting GLP-2 analog) for short bowel syndrome

  • In June 2016, glepaglutide was proposed as an International Non-proprietary Name for Zealand's proprietary GLP-2 analog, previously known as ZP1848.
  • The ongoing Phase II Proof-of-Concept trial is progressing according to plan, with results expected mid-2017.

Dasiglucagon [4] (ZP4207, glucagon analog) for single-dose rescue treatment of severe hypoglycemia in diabetes                                                                                 

  • In August 2016, Zealand announced results from a clinical Phase II trial with dasiglucagon, supporting its potential as a ready-to-use rescue pen to treat acute, severe hypoglycemia ("insulin shock") associated with insulin therapy in diabetes. 
  • Zealand initiated the trial in February 2016 and completed the enrolment of 58 patients with type 1 diabetes in June 2016.
  • The full results from the Phase II trial are planned for discussion with the FDA later in 2016 to define the next development steps for dasiglucagon as a rescue treatment.  

Dasiglucagon [5] (ZP4207, glucagon analog) for multiple-dose use in dual-hormone artificial pancreas for better diabetes management                                                                                                    

  • In June 2016, a non-exclusive collaboration was announced with U.S. based Beta Bionics. The objective is to advance the development of a first-in-class dual-hormone artificial pancreas system to offer diabetes patients on insulin therapy, an easier and better way to control and manage their disease.
  • A next clinical trial is expected to be initiated later in 2016.

Other business

  • As of 1 July 2016, Zealand's senior management team has been expanded and strengthened with the arrival of Andrew Parker as the company's new Chief Science Officer.

        

Financial guidance for 2016 unchanged Zealand maintains its revenue guidance for the full-year. This includes expectations of growing royalty revenue from Sanofi's sales of lixisenatide; as Lyxumia ® outside the U.S. and potentially as Adlyxin TM in the U.S. pending launch in 2016.

Expectations of revenue of up to DKK 200 million / €27 million in the form of milestone payments from partners are also unchanged.  

Net operating expenses in 2016 are expected at a range of DKK 340-360 million / €45-48 million, and operating loss before royalty income/expenses is therefore expected at a range of DKK 140-160 million / €19-21 million.

Conference call with senior management today at 2:00 pm CET / 8:00 am EDT Zealand's senior management will host a conference call today at 2:00 pm CET/ 8:00 am EDT to present the interim report for H1 2016. Participating in the call will be Britt Meelby Jensen, Chief Executive Officer, Mats Blom, Chief Financial Officer, Adam Steensberg, Chief Medical and Development Officer and Hanne Leth Hillman, SVP and Head of IR and Communications. The presentation will be followed by a Q&A session.

The conference call will be conducted in English and the dial-in numbers are:

DK standard access             +45 32 71 16 60 UK and international            +44 (0) 207 136 6283 US (free dial-in from NYC) +1 646 254 3388

Passcode for access           79 59 175

A live audio webcast of the call including an accompanying slide presentation will be available via the following link, http://edge.media-server.com/m/p/m4rcono7 , accessible also from Zealand's website ( www.zealandpharma.com ). Participants are advised to register for the webcast approximately 10 minutes before the start.

A replay of the event will be made available from the investor section of Zealand's website following the call.

  *****

Britt Meelby Jensen, President and Chief Executive Officer Tel: +45 51 67 61 28, email: bmj@zealandpharma.com

Hanne Leth Hillman, Senior Vice President, Investor Relations and Communications Tel: +45 50 60 36 89, email : hlh@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn and a pipeline of proprietary product candidates, which primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analog for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia ® outside the United States and approved as Adlyxin TM in the United States. Lixisenatide has been developed in a fixed-ratio combination with Lantus ® (insulin glargine) which product is under regulatory review in the United States and in Europe. 

Zealand's proprietary pipeline includes: Dasiglucagon * (ZP4207) as single-dose rescue treatment for acute, severe hypoglycemia (Phase II); Glepaglutide** (ZP1848) for treatment of short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon is a proposed International Nonproprietary Name (pINN) ** Glepaglutide is a proposed International Nonproprietary Name (pINN) 

[1] Dasiglucagon is a proposed International Nonproprietary Name (pINN).

[2] Glepaglutide is a proposed International Nonproprietary Name (pINN).

[3] Glepaglutide is a proposed International Nonproprietary Name (pINN).

[4] Dasiglucagon is a proposed International Nonproprietary Name (pINN).

[5] Dasiglucagon is a proposed International Nonproprietary Name (pINN).

33-16_0825 Company announcement - H1 2016 interim report http://hugin.info/136974/R/2037181/759041.pdf

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 39

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 114

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 84

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 67

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 0

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Frontline Healthcare Partners Secures Integracare Inc. Deal

Updated Category News Views 161

Frontline Healthcare Partners Expands Through Strategic Acquisition Frontline Healthcare Partners has recently made headlines with its strategic acquisition of Integracare Inc.. This move indicates a significant step forward in enhancing its portfolio within the private home healthcare space. With Integracare’s reputation for quality care in Toronto and Mississauga,...

Continue Reading
WiMi Innovates with Advanced FPGA-Based Quantum Computing Tech

Updated Category News Views 147

WiMi Hologram Cloud Inc. Develops Cutting-Edge Quantum Computing Technology WiMi Hologram Cloud Inc. (NASDAQ: WiMi), a global leader in Hologram Augmented Reality (AR) technology, has achieved a remarkable milestone by developing a digital quantum computer verification technology based on Field-Programmable Gate Array (FPGA). This advancement signifies a transformative...

Continue Reading
KSP Achieves Excellence in Specialty Pharmacy Recognition Again

Updated Category News Views 244

KSP Recognized as a Specialty Pharmacy Leader KSP, part of McLaren's Specialty Pharmacy, has once again been honored for its outstanding achievements in performance measurement. The Utilization Review Accreditation Commission (URAC) has recognized KSP as a 2024 Specialty Pharmacy Pioneer in its Leaders in Performance Measurement (LPM) program. This accolade underlines...

Continue Reading
Why IREN Limited Shares Are Under Pressure Today in Market

Updated Category News Views 237

Understanding the Recent Drop in IREN Limited Stock IREN Limited (NASDAQ: IREN) has experienced a noticeable decline in share price today as investors react to the company's recent announcements. This comes as a surprise to some, as IREN has shown potential for growth in the past year. Recent Announcements from IREN Limited In a recent update, IREN Limited unveiled plans...

Continue Reading
Deutsche Bank Adjusts S&P 500 Forecast to 5,750 Points

Updated Category News Views 57

Deutsche Bank Updates S&P 500 Year-End Forecast Deutsche Bank has adjusted its year-end target for the S&P 500 index, now forecasting it to reach 5,750 points, up from the previous estimate of 5,500. This significant change stems from strong corporate earnings, an increase in stock buybacks, and a solid demand for equities among investors. Positive Earnings Growth Ahead...

Continue Reading